Methyl 4-methoxyacetoacetate

We are Methyl 4-methoxyacetoacetate CAS:41051-15-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   Methyl 4-methoxyacetoacetate
CAS.NO:  41051-15-4
Synonyms:
methyl 4-methoxy-3-oxobutanoate
4-Methoxyacetoacetic Acid Methyl Ester

Molecular Formula: C6H10O4
Molecular Weight:  146.14100

Physical and Chemical Properties:
Density: 1.129 g / mL at 25 ° C (lit.)
Boiling point: 89 ° C8.5 mm Hg (lit.)
Melting point: -80 ° C
Flash point: 193 ° F
Refractive index: 1.411

Specification:
Appearance: Colorless to yellow liquid
Purity:≥99.0%
Water:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Cabotegravir CAS:1051375-10-0

Methyl 4-methoxyacetoacetate


Related News: In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.3-Fluoropicolinic acid In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.(2S,4S)-1-(tert-butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid CAS:1378388-16-9 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.74333-44-1 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.

Related Products
Product Name
4-(4-Methylpiperazinomethyl)benzoic Acid Dihydrochloride View Details
Methyltriacetoxysilane View Details
2′-Bromo-4′-fluoroacetophenone View Details
2H,4H,5H,6H,7H,7AH-Thieno[3,2-c]pyridin-2-one hydrochloride manufacturer 1-Bromo-4-tert-butylbenzene manufacturer 2-Methyl-4-amino-6-methoxy-s-triazine manufacturer 4-Fluoro-3-nitrobenzoic acid manufacturer 1-Methyl-3-phenylpiperazine manufacturer